Innate Pharma S.A. (IPHA)
| Market Cap | 162.13M |
| Revenue (ttm) | 14.84M |
| Net Income (ttm) | -54.08M |
| Shares Out | 92.16M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,952 |
| Open | 1.710 |
| Previous Close | 1.740 |
| Day's Range | 1.700 - 1.791 |
| 52-Week Range | 1.570 - 2.630 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+191.55%) |
| Earnings Date | Mar 26, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]
Financial Performance
In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 191.55% from the latest price.
News
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of February 19, 2026.
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate pharma to participate in the Leerink Partners Global Healthcare Conference.
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities...
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities...
Innate Pharma Releases Its 2026 Financial Calendar
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March...
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025.
Innate Pharma to Present at Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Congress--Innate Pharma to present at Jefferies Global Healthcare Conference.
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Innate Pharma S.A. ( IPHA) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonath...
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial...
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Admin...
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conf...
Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stép...
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and ...
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia...
Innate Pharma Reports First Half 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results.
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces its participation in the 25th edition of the European Midcap Event.
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces conference call and webcast for first half 2025 financial results and business update.
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)-- #IRConference--Innate Pharma announces its participation in BTIG virtual biotechnology conference.
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for ...
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...
Outcome of Innate Pharma's 2025 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...